A first in COPD treatment: Revefenacin receives FDA approval
The first once-daily nebulized bronchodilator has received FDA approval as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).

Revefenacin, a long-acting muscarinic antagonist, is expected to be available by the end of this year. It will be marketed as Yupelri. The drug should not be used as rescue therapy for acute bronchospasm episodes or during acute exacerbations.

Source: https://jamanetwork.com/journals/jama/fullarticle/2718777
Dr. R●●●t P●●●●y and 2 other likes this
Like
Comment
Share